Inspections find no concerns with vaccine production

No quality and safety issues were found in vaccines that are currently under production in China, the State Drug Administration said after a thorough inspection.

After Changchun Changsheng Bio-tech Co in Jilin province was found to have fabricated production records for freeze-dried rabies vaccines for human use and was linked to a substandard DTaP vaccine for infants in July, the administration sent out teams to the other 45 Chinese vaccine manufactures to conduct inspections on vaccine production from July 23 to Aug 9, according to a statement released by the administration on Friday evening.

Besides the seven manufacturers that have suspended production for more than three years, the other 38 manufacturers that are currently producing vaccines have relatively comprehensive quality control systems as required. Also, all the vaccines produced are up to standard, the statement said.